<!DOCTYPE html>
<html lang="en">

<head>
    <title>COVID19-VISUALIZER</title>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

    
    <!-- <script src='https://cdn.plot.ly/plotly-2.20.0.min.js'></script> -->
    <script src='https://cdnjs.cloudflare.com/ajax/libs/d3/3.5.17/d3.min.js'></script>
    <script type="text/javascript" src="https://canvasjs.com/assets/script/jquery-1.11.1.min.js"></script>
    <script type="text/javascript" src="https://cdn.canvasjs.com/canvasjs.stock.min.js"></script>
    <script src="https://cdn.plot.ly/plotly-latest.min.js"></script>
    <script src="http://d3js.org/d3.v4.js"></script>
    <script src="https://d3js.org/d3-scale-chromatic.v1.min.js"></script>
    <script src="https://d3js.org/d3-geo-projection.v2.min.js"></script>
    <!-- <link rel="stylesheet" href="https://pyscript.net/latest/pyscript.css" />
  <script defer src="https://pyscript.net/latest/pyscript.js"></script> -->
    <!-- bootstrap css -->
    <link rel="stylesheet" type="text/css" href="css/bootstrap.min.css">
    <!-- style css -->
    <link rel="stylesheet" type="text/css" href="css/style.css">
    <!-- Responsive-->
    <link rel="stylesheet" href="css/responsive.css">
    <!-- fevicon -->
    <link rel="icon" href="images/fevicon.png" type="image/gif" />

    <!-- Tweaks for older IEs-->
    <link rel="stylesheet" href="https://netdna.bootstrapcdn.com/font-awesome/4.0.3/css/font-awesome.css">



</head>

<body>

    <div class="header_main">
        <div class="container">
            <div class="logo">
                <div class="font2"> COVID19-VISUALIZER WORLD VACCINATION</div>
            </div>
        </div>
    </div>
    </div>
    <div class="header">
        <div class="container">
            <!--  header inner -->
            <div class="col-sm-12">

                <div class="menu-area">
                    <nav class="navbar navbar-expand-lg ">
                        <!-- <a class="navbar-brand" href="#">Menu</a> -->
                        <button class="navbar-toggler collapsed" type="button" data-toggle="collapse" data-target="#navbarSupportedContent" aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation">
                       <i class="fa fa-bars"></i>
                        </button>
                        <div class="collapse navbar-collapse" id="navbarSupportedContent">
                            <ul class="navbar-nav mr-auto">
                                <li class="nav-item active">
                                    <a class="nav-link" href="#">HOME<span class="sr-only">(current)</span></a> </li>
                                <li class="nav-item" href="#">
                                    <a class="nav-link" href="#">CONTACT</a></li>
                            </ul>
                        </div>
                    </nav>
                </div>
            </div>
        </div>
    </div>
    <!--banner start -->
    <div class="banner-main">
        <div class="container">
            <div id="main_slider" class="carousel slide" data-ride="carousel">
                <!-- The slideshow -->
                <div class="carousel-inner">
                    <div class="carousel-item active">
                        <div class="titlepage-h1">
                            <h1 class="bnner_title">Welcome To<br>
                                <span style="color: #10b5fa">Null team </span></h1>
                            <p class="long_text">We are going to analize world vaccination data to understand the progress of vaccination from 4Dec20 to 30Mar22</p>
                        </div>
                        <div class="btn_main">
                            <button type="button" class="btn btn-dark btn-lg"><a href="https://en.wikipedia.org/wiki/COVID-19_vaccine">Covid19 Vaccine</a></button>
                        </div>
                    </div>
                    <div class="carousel-item">
                        <div class="titlepage-h1">
                            <h1 class="bnner_title">Member<br>
                                <span style="color: #10b5fa">Le Cao Nhat Hoang - ITITIU20205</span></h1>

                        </div>
                        <div class="btn_main">

                            <button type="button" class="btn btn-dark btn-lg"><a href="https://github.com/vinhkute24" >INFO</a></button>
                        </div>
                    </div>
                    <div class="carousel-item">
                        <div class="titlepage-h1">
                            <h1 class="bnner_title">Member<br>
                                <span style="color: #10b5fa">Huynh Le Son-ITITIU19202</span></h1>

                        </div>
                        <div class="btn_main">
                            <button type="button" href="#" class="btn btn-dark btn-lg">INFO</button>
                        </div>
                    </div>
                    <div class="carousel-item">
                        <div class="titlepage-h1">
                            <h1 class="bnner_title">Member<br>
                                <span style="color: #10b5fa">Nguyen Tien Gia Nguyen - ITITIU19035</span></h1>

                        </div>
                        <div class="btn_main">
                            <button type="button" href="#" class="btn btn-dark btn-lg">INFO</button>
                        </div>
                    </div>
                    <div class="carousel-item">
                        <div class="titlepage-h1">
                            <h1 class="bnner_title">Member<br>
                                <span style="color: #10b5fa">Truong Tan Phat-ITITIU20140</span></h1>

                        </div>
                        <div class="btn_main">
                            <button type="button" href="#" class="btn btn-dark btn-lg">INFO</button>
                        </div>
                    </div>
                    <div class="carousel-item">
                        <div class="titlepage-h1">
                            <h1 class="bnner_title">Member<br>
                                <span style="color: #10b5fa">Vo Trung Duong-ITITIU20193</span></h1>

                        </div>
                        <div class="btn_main">
                            <button type="button" href="#" class="btn btn-dark btn-lg">INFO</button>
                        </div>
                    </div>
                </div>
                <a class="carousel-control-prev" href="#main_slider" role="button" data-slide="prev">
                    <i class="fa fa-angle-left"></i>
                </a>
                <a class="carousel-control-next" href="#main_slider" role="button" data-slide="prev">
                    <i class="fa fa-angle-right"></i>
                </a>
            </div>
        </div>
    </div>
    <!--banner end -->
    <!--services start -->

    <div class="services_main">
        <div class="container">
            <div class="creative_taital">
                <h1 class="creative_text">COVID-19 vaccine development</h1>
                <p style="color: #050000; text-align: center;">SARS-CoV-2 vaccines, encompassing various types like viral vector, protein subunit, mRNA, and others, play a crucial role amid evolving virus variants. While they enhance immune responses, concerns exist, such as thrombocytopenia and myocarditis with some vaccines. Evaluation includes diverse populations like pregnant women, the elderly, and immunocompromised individuals. Despite complications, governments are urged to continue vaccination, emphasizing monitoring, timely intervention, and ongoing research for improved safety and efficacy. Exploring measures like mix-and-match vaccination, nanoparticle vaccines, and optimizing immune adjuvants is recommended to address concerns and enhance overall vaccine performance.
                </p>
            </div>

            <div class="section_service_2">
                <h1 class="service_text">Countries Daily Vaccination</h1>
                <a href="bar.html" class="bar-link">
                    <img src="images/bar.png" alt="bar Image">
                </a>
            </div>
            <div id="my_dataviz"></div>

            <script src="Bar.js"></script>
            </div>

            <div class="section_service_2">
                <h1 class="service_text">Total Vaccines Provided To Countries</h1>
                <a href="map.html" class="map-link">
                    <img src="images/map.png" alt="Map Image">
                </a>
            </div>

            <div class="section_service_2">
                <h1 class="service_text">People Vaccinated In Countries</h1>
                <a href="line.html" class="line-link">
                    <img src="images/line.png" alt="Line Image">
                </a>
            </div>
            <script src="Line.js"></script>
            <div id="line-container"></div>
            <div class="section_service_2">
                <h1 class="service_text">Covid19 Vaccination Adverse Events</h1>
            </div>
            <div class="service_main">
                <div class="container">
                    <div class="row">
                        <div class="col-md-6">
                            <div class="written_text">
                                <div class="like_icon"><img src="images/writing-icon.png"></div>
                                <h1 class="written_text">MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN AND ADULTS</h1>
                                <p>In Ontario, 16 reports of multisystem inflammatory syndrome in children and adults (MIS-C/A) have
                                    been reported to date, with 14 of these reports meeting the provincial case definition. The 14 cases
                                    include 9 following Pfizer-BioNTech Comirnaty COVID-19, and 5 following Moderna Spikevax COVID-19
                                    vaccine,. All reports of MIS-C/A are assessed using the Brighton Collaboration standard definition of
                                    MIS-C/A.
                                     Six reports among persons under 21 years of age met level 1 of the Brighton Collaboration
                                    case definition of MIS-C and three reports met level 2A. Among persons 21 years of age and older, based
                                    on the clinical presentation and other indicators, three reports met level 1 of the Brighton Collaboration
                                    case definition of MIS-A and two reports had insufficient evidence to meet level 1, 2, or 3 (i.e., met level
                                    4 diagnostic certainty) of the case definition. </p>
                            </div>
                        </div>
                        <div class="col-md-6">
                            <div class="written_text">
                                <div class="like_icon"><img src="images/writing-icon.png"></div>
                                <h1 class="written_text">MYOCARDITIS/PERICARDITIS</h1>
                                <p>Rare myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around
                                    the heart) events have been reported following vaccination with COVID-19 mRNA vaccines.
                                    Information from vaccine safety monitoring systems and evidence from multiple observational studies
                                    across many countries support an association between COVID-19 mRNA vaccines and an increased risk
                                    of myocarditis/pericarditis. Information to date indicates that these events occur more commonly
                                    after the second dose, within the week following vaccination (typically within 4-5 days), mainly in
                                    adolescents/young adults 12 to 29 years of age, and more often in males than females.
                                    Vaccine safety surveillance data in Canada suggest relatively higher rates of myocarditis/pericarditis
                                    reported after Moderna Spikevax COVID-19 vaccine compared to Pfizer-BioNTech Comirnaty COVID-19
                                    vaccine. Similar trends have been observed in Ontario’s vaccine safety surveillance data where the
                                    reporting rates of myocarditis/pericarditis was observed to be higher following vaccination with
                                    Moderna Spikevax COVID-19 vaccine compared to Pfizer-BioNTech Comirnaty COVID-19 vaccine in the
                                    18 to 24 year old age group, particularly among males. </p>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="service_main">
                <div class="container">
                    <div class="row">

                        <div class="col-md-6">
                            <div class="written_text">
                                <div class="like_icon"><img src="images/writing-icon.png"></div>
                                <h1 class="written_text">THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME (TTS) </h1>
                                <p>Thrombosis with thrombocytopenia syndrome (TTS) is a serious health condition characterized by the
                                    presence of acute venous or arterial thrombosis (blood clot) with new onset thrombocytopenia (low
                                    levels of platelets), and no known recent exposure to heparin. TTS emerged in 2021 as a new adverse
                                    event following immunization with COVID-19 adenoviral vector-based vaccines, including AstraZeneca
                                    Vaxzevria/COVISHIELD and Janssen Jcovden COVID-19 vaccines. Vaccine-Induced Immune Thrombotic
                                    Thrombocytopenia (VITT) refers to the clinical syndrome of TTS, in addition to laboratory tests that
                                    confirm platelet activation (i.e., anti-platelet 4 antibodies).</p>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

        </div>
    </div>
    <!--Contact_section end -->

    <div class="container">
        <div class="row">
            <div class="col-sm-12">
                <div class="section_service_">
                    <h1 class="service_text">Conclusion</h1>
                </div>
                <div class="container">


                    <p style="color: #050000; text-align: justify;">Final decisions on the number of vaccines and the particular vaccines selected for accelerated development must incorporate various nonquantifiable factors, as well as information provided by the rankings that were derived with the proposed system for calculating benefits and expenditures. The additional factors include: goals of the responsible agency and its schedule for achieving them, ethical questions on the distribution of benefits among socioeconomic or age groups, countries, or regions, most appropriate points in the development process at which the agency can exert influence and the opportunity and need for such influence, extent of private sector activities, opportunities to accelerate vaccine development through collaboration with other countries or international organizations, the desired balance of the development portfolio (e.g., pediatric versus adult vaccines, global versus regional diseases), arguments for treating certain vaccine development projects as unique because of their potential for facilitating immunization programs in general (e.g., by eliminating constraints on delivery, such as poor stability) or by improving public confidence (e.g., by reducing adverse reactions), the prospect that a particular project may serve as a useful model for a number of other desired vaccines, disease related factors, such as epidemiologic and clinical characteristics likely to overwhelm medical services, and the availability of alternative control strategies or safe and effective therapy, possible synergistic interaction with other diseases, the immediate U.S. interest in diseases that may be imported into the United States, that threaten travelers or personnel stationed overseas, or that are existing problems in the United States, the affordability of the potential health benefit, if not already used formally in the decision process
                    </p>



                </div>
            </div>
        </div>

        <!--Contact_section start -->
        <div class="contact_main">
            <div class="container">
                <div class="row">
                    <div class="col-sm-12">
                        <h1 class="touch_text">Contact Us</h1>
                    </div>
                </div>
            </div>
            <div class="contact_section_2">
                <div class="container">
                    <div class="row">
                        <div class="col-sm-4">
                            <div class="map_icon">
                                <img src="images/map-icon.png" style="max-width: 100%;padding-left: 30px; ">
                                <p class="email-text"><a href="#">International University<br>HCM</a></p>
                            </div>
                        </div>
                        <div class="col-sm-4">
                            <div class="map_icon">
                                <img src="images/call-icon.png" style="max-width: 100%;padding-left: 30px;">
                                <p class="email-text"><a href="#">+123456789</a></p>
                            </div>
                        </div>
                        <div class="col-sm-4">
                            <div class="map_icon">
                                <img src="images/email-icon.png" style="max-width: 100%; padding-left: 30px;">
                                <p class="email-text"><a href="#">NullTeam@gmail.com</a></p>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <!--Contact_section end -->
        <div class="copyright">
            <div class="container">
                <div class="row">
                    <div class="col-sm-12">
                        <p class="copyright_text">© 2023 All Rights Reserved. <a href="https://html.design">Null Team</a></p>
                    </div>
                </div>
            </div>
        </div>



        <!-- Javascript files-->
        
        <script src="js/bootstrap.bundle.min.js"></script>       
</body>

</html>
